Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 28 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the glutamine synthetase gene. Use of said variant and derived products for improving expression system for the production of recombinant protein.
1. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers,
said first monomer has a sequence that is at least 97% identical to SEQ ID NO: 271 and said second monomer has a sequence that is at least 97% identical to SEQ ID NO: 246 and
wherein said DNA target sequence is SEQ ID NO: 30.
2. The method of claim 1 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
3. The method of claim 1 , wherein said contacting is in a cell.
4. The method of claim 1 , wherein said I-CreI variant is expressed in a cell from a polynucleotide encoding said I-CreI variant.
5. The method of claim 1 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
6. The method of claim 1 , further comprising insertion of a transgene at the locus of the DNA target sequence in the glutamine synthetase gene.
7. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers, wherein at least one substitution is of a residue in the range of positions 28 to 40 of I-CreI and at least one substitution is of a residue in the range of positions 44 to 77 of I-CreI and
wherein said variant is a heterodimer, resulting from the association of a first and a second monomer having different mutations in positions 28 to 40 and 44 to 77 of I-CreI and wherein the first monomer and the second monomer, respectively, are selected from the following pairs of sequences:
(i) one of SEQ ID NO: 61 to 84 (first monomer) and one of SEQ ID NO: 85 to 108 (second monomer);
(ii) one of SEQ ID NO: 63 and 109 to 128 (first monomer) and one of SEQ ID NO: 89 and 129 to 151 (second monomer); and
(iii) one of SEQ ID NO: 63, 109, 110, 113, 123, 127, and 152 to 163 (first monomer) and one of SEQ ID NO: 89, 130 to 134, 136, 146, 147, 164 to 175, 198-200, 203, and 206 to 208 (second monomer).
8. The method of claim 7 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
9. The method of claim 7 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
10. The method of claim 7 , further comprising insertion of a transqene at the locus of the DNA target sequence in the glutamine synthetase gene.
11. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers,
wherein at least one substitution is of a residue in the range of positions 28 to 40 of I-CreI and at least one substitution is of a residue in the range of positions 44 to 77 of I-CreI and
wherein said variant is a heterodimer, resulting from the association of a first and a second monomer having different mutations in positions 28 to 40 and 44 to 77 of I-CreI and
wherein at least one of the two I-CreI monomers has at least 95% sequence identity with one of the sequences selected from the group consisting of: SEQ ID NO: 61-136, 138-144, 147-175, 198-200, 203, and 206-208.
12. The method of claim 11 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
13. The method of claim 11 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
14. The method of claim 11 , further comprising insertion of a transqene at the locus of the DNA target sequence in the glutamine synthetase gene.
15. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers,
wherein at least one substitution is of a residue in the range of positions 28 to 40 of I-CreI and at least one substitution is of a residue in the range of positions 44 to 77 of I-CreI and
wherein said target sequence is SEQ ID NO: 30 and
wherein said I-CreI variant comprises a first monomer having any of SEQ ID NO: 211 to 229, 242 to 244 and 271 and a second monomer having any of SEQ ID NO: 245 to 268.
16. The method of claim 15 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
17. The method of claim 15 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
18. The method of claim 15 , further comprising insertion of a transgene at the locus of the DNA target sequence in the glutamine synthetase gene.
19. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said I-CreI variant comprises at least two substitutions in at least one of the monomers,
wherein at least one substitution is of a residue in the range of positions 28 to 40 of I-CreI and at least one substitution is of a residue in the range of positions 44 to 77 of I-CreI and
wherein said target sequence is SEQ ID NO: 30 and
wherein said I-CreI variant comprises a first monomer having at least 97% sequence identity with one of the sequences selected from the group consisting of: SEQ ID NO: 211 to 229, 242 to 244 and 271, and a second monomer having at least 97% sequence identity with one of the sequences selected from the group consisting of: SEQ ID NO: 245 to 268.
20. The method of claim 19 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
21. The method of claim 19 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
22. The method of claim 19 , further comprising insertion of a transgene at the locus of the DNA target sequence in the glutamine synthetase gene.
23. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said first monomer having has the sequence of SEQ ID NO: 271, and said second monomer having has the sequence of SEQ ID NO: 246, and
wherein said DNA target sequence is SEQ ID NO: 30.
24. The method of claim 23 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
25. The method of claim 23 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
26. The method of claim 23 , further comprising insertion of a transgene at the locus of the DNA target sequence in the glutamine synthetase gene.
27. A method of cleaving a DNA target sequence from a glutamine synthetase gene comprising contacting said DNA target sequence with an I-CreI variant to thereby cleave said DNA target sequence
wherein said I-CreI variant comprises a first monomer and a second monomer which are associated to form an active form,
wherein said first monomer has a sequence that is at least 97% identical to one of the sequences selected from the group consisting of SEQ ID NO: 212, 215, and 271, and said second monomer has a sequence that is at least 97% identical to one of the sequences selected from the group consisting of SEQ ID NO: 130, 246, 250, and 264, and
wherein said DNA target sequence is SEQ ID NO: 30.
28. The method of claim 27 , wherein said first monomer has a sequence selected from the group consisting of SEQ ID NO: 212, 215, and 271, and said second monomer has a sequence selected from the group consisting of SEQ ID NO: 130, 246, 250, and 264.
29. The method of claim 27 , wherein said variant is a single-chain chimeric meganuclease comprising two I-CreI monomers.
30. The method of claim 27 , wherein the cleavage of the DNA target sequence leads to a glutamine synthetase knock-out cell line.
31. The method of claim 27 , further comprising insertion of a transqene at the locus of the DNA target sequence in the glutamine synthetase gene.